-

Thermo Fisher Scientific Expands Clinical Research Laboratory in Kentucky

The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today announced the expansion of its central laboratory operations in Kentucky dedicated to accelerating pharmaceutical and biotech customers’ delivery of safe, effective medicines to patients.

The business will expand its sample management and biorepository operations in a new 65,000-square-foot space in Covington, enabling further capability expansion at its existing site in nearby Highland Heights. Thermo Fisher’s $47.8 million investment is expected to create more than 250 new jobs across the two sites over the next eight years, with renovation and construction anticipated to begin later this year.

The PPD clinical research business has operated a central lab operation in Highland Heights since 2002, and today it includes central lab services, biomarker operations, sample management and testing to support new therapeutics, including vaccines and cell and gene therapy products. The renovation of an existing building on West 38th Street in Covington will significantly expand the business’ labs footprint.

“Our central lab plays a vital role in helping our customers make timely, efficient and informed decisions about their clinical trials and ensure patient safety,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “Our expansion will enhance their ability to advance life-changing research. We are excited to expand into Covington and grow our operations in Highland Heights as a vital part of our global labs capabilities serving our customers. We value the support of state and local officials as we continue to hire talented colleagues to advance our company’s Mission to enable our customers to make the world healthier, cleaner and safer.”

“The commonwealth is seeing tremendous growth in its health care and life-sciences sectors, providing high-paying, quality jobs for Kentucky residents across the state,” said Kentucky Gov. Andy Beshear. “I am thrilled to see Thermo Fisher once again choose Kentucky to locate and expand its business. I look forward to the company’s continued success here in the commonwealth as this continued investment will be a welcomed addition to the Northern Kentucky region.”

The Highland Heights central lab, which employs more than 600 analytical laboratory staff, scientific and support professionals, and Ph.D.-level scientists, offers safety testing including automated chemistry, urinalysis and hematology, anatomic pathology, flow cytometry, microbiology and molecular assays. The central lab also offers a wide variety of other services, such as clinical sample management, processing and storage, kit design and preparation for collection of clinical samples, and sample testing services. The biomarker lab provides support for regulated biomarkers with immunoassays, flow cytometry and molecular assays.

In addition to the Highland Heights facility, Thermo Fisher’s clinical research business has biomarker and central labs in Brussels, Belgium, and Singapore; bioanalytical, biomarker and vaccine sciences labs in Richmond, Virginia; bioanalytical and good manufacturing practices (GMP) labs in Middleton, Wisconsin; a GMP lab in Athlone, Ireland; and bioanalytical, biomarker, vaccine sciences and central labs in Suzhou, China.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Name: Nadine Maeser
Email: nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD clinical research business announced the expansion of its central laboratory operations in Kentucky.
Release Versions

Contacts

Media Contact Information:
Name: Nadine Maeser
Email: nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom